Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
Johanna C. Bendell
No relevant relationships to disclose
Chloe Evelyn Atreya
No relevant relationships to disclose
Thierry André
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche; Sanofi ; Taiho Pharmaceutical
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
Michael S. Gordon
Research Funding - GlaxoSmithKline
Rene Bernards
No relevant relationships to disclose
Eric Van Cutsem
No relevant relationships to disclose
Sabine Tejpar
Other Remuneration - GlaxoSmithKline
Roger Sidhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
William Y. Go
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Alicia Allred
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Monica Motwani
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Benjamin B. Suttle
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Yuehui Wu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Axel Hoos
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Keith W. Orford
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ryan Bruce Corcoran
No relevant relationships to disclose
Jan HM Schellens
No relevant relationships to disclose